Evidence map›Paper›PMID 38698783›Full record

ReviewFrontiers in medicine2024

Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment.

Malik A Althobiani, Anne-Marie Russell, Joseph Jacob, Yatharth Ranjan, Amos A Folarin, John R Hurst, Joanna C Porter

Registry-linked trialAbstract readReview
In one paragraph

Review in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07205627 (Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Diseases and Its Impact on Quality of Life During the Period July-December 2025 at AHCGFAA), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07205627 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Diseases and Its Impact on Quality of Life During the Period July-December 2025 at AHCGFAA

TypeinterventionalSponsorHospital Civil de GuadalajaraRan2025 to 2025Enrolled20ConditionsLung Disease Interstitial DiffuseArmsRehabilitation program
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Association ofInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Malik A AlthobianiRoyal Free Campus, UCL Respiratory, University College London, London, United Kingdom.
Anne-Marie RussellSchool of Health and Care Professions, University of Exeter, Exeter, United Kingdom.
Joseph JacobUCL Respiratory, University College London, London, United Kingdom.
Yatharth RanjanInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Amos A FolarinInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
John R HurstRoyal Free Campus, UCL Respiratory, University College London, London, United Kingdom.
Joanna C PorterUCL Respiratory, University College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial lung diseases (ILDs) refer to a heterogeneous and complex group of conditions characterized by inflammation, fibrosis, or both, in the interstitium of the lungs. This results in impaired gas exchange, leading to a worsening of respiratory symptoms and a decline in lung function. While the etiology of some ILDs is unclear, most cases can be traced back to factors such as genetic predispositions, environmental exposures (including allergens, toxins, and air pollution), underlying autoimmune diseases, or the use of certain medications. There has been an increase in research and evidence aimed at identifying etiology, understanding epidemiology, improving clinical diagnosis, and developing both pharmacological and non-pharmacological treatments. This review provides a comprehensive overview of the current state of knowledge in the field of interstitial lung diseases.

Indexed as

hypersensitivity pneumonitisidiopathic pulmonary fibrosisinterstitial lung diseasenonspecific interstitial pneumoniasarcoidosis

Identifiers

PMID38698783
PMCPMC11063378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.